Early trial aims to boost Chemo's punch against tough leukemia
NCT ID NCT04659616
Summary
This early-stage study is testing if adding a new oral drug called pemigatinib after standard chemotherapy is safe and helpful for adults newly diagnosed with a higher-risk form of acute myeloid leukemia (AML). The goal is to see if blocking a specific growth signal in cancer cells can improve treatment outcomes. Researchers will first find the safest dose and then see if it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UT Southwestern/Simmons Cancer Center-Dallas
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.